Strategic Communication and Public Relations

Ependymoma Awareness Day celebrating breakthroughs in cooperative ependymoma research

No. 16c | 10/04/2014

Ependymoma is a rare but aggressive brain tumor that occurs in both children and adults. Only large international collaborative efforts such as the Cooperative Ependymoma Research Network (CERN) and the Ependymoma Consensus Conference Series enable researchers and clinicians worldwide to decipher the biology, design innovative clinical trials, and ultimately improve survival of patients suffering from this devastating disease. Scientists at the German Cancer Research Center have significantly contributed to the latest breakthroughs in ependymoma research.

© dkfz.de

Patients, clinicians and researchers celebrate this year´s Ependymoma Awareness Day on April 10, 2014, a year in which we have witnessed some major breakthroughs in ependymoma research that will hopefully lay the ground for novel treatment approaches in the near future.

At any age Ependymoma can arise in different compartments of the central nervous system (CNS) including the spine, the cerebellum, and the cortex. These tumors comprise a collection of biologically distinct entities that cannot be reliably distinguished by conventional pathology analysis. It is very likely that only when we account for these different biological entities in clinical trials we will be able to design appropriate treatments for all patients.

A few years ago, groups from both North America and Europe established a unique collaboration that has enabled scientific breakthroughs in this rare disease.This collaboration includes the sharing of tumor samples to analyze and discuss novel biological insights. The Cooperative Ependymoma Research Network (CERN) under the leadership of Dr. Mark Gilbert (MD Anderson Cancer Center, Houston, USA) as well as the Ependymoma Consensus Conference Series jointly organized by Dr. Michael Taylor (Hospital for Sick Children, Toronto, Canada), Richard Gilbertson (St. Jude Children´s Research Hospital, Memphis, USA), and Stefan Pfister (German Cancer Research Center and University Hospital, Heidelberg, Germany) are two prominent examples for such world-wide collaborative networks in ependymoma.

Using this infrastructure research groups on both sides of the Atlantic were recently able to report significant breakthroughs in our understanding of ependymomas occurring both in the cortex and in the cerebellum.

Richard Gilbertson and David Ellison at St. Jude´s Children´s Research Hospital were able to identify a highly recurrent fusion gene in the vast majority of cortical ependymomas. This discovery is leading to the development of new drugs that target this tumor-specific mutation and do not hurt healthy cells.

In cerebellar ependymoma, groups from Toronto (Michael Taylor), Houston (Ken Aldape) and Heidelberg (Andrey Korshunov, Hendrik Witt and Stefan Pfister) have identified two biologically very distinct disease variants, which typically occur in different ages, and are also associated with different outcome. Furthermore, the researchers could demonstrate that the subtype that appears to behave more aggressive seems to be driven by aberrations in the epigenetic code, information in cells that is transmitted to daughter cells outside of the DNA code. Similar as for cortical ependymomas, this again for the first time offers the possibility for the identification of drugs that directly target this “Achilles’ Heel” of aggressive ependymomas in the cerebellum.

In summary, patients, clinicians and researchers collectively fighting against Ependymoma have good reasons to hope for new therapeutic options in the near future. The Ependymoma Awareness Day intends to sensitize a larger public for the need of more attention for this rare, but still devastating disease.

The Federal Ministry of Science, Research and Arts of Baden Württemberg and the German Cancer Research Center Heidelberg strongly support this initiative.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS